CSCO直播

肺癌口头报告专场

共同主席：赫捷、周彩存、束永前

特邀嘉宾：王思愚、陈公琰、赵琼

肺癌口头报告专场-论文交流-第一节

主持人：赫捷、周彩存

08:30~08:40

Long-term Survival With Nivolumab in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

陆舜上海市胸科医院

08:40~08:50

The role of BIM Deletion Polymorphism in Gefitinib treated Advanced Non–Small-Cell Lung Cancer patients with EGFR mutation

张莉华中科技大学同济医学院附属同济医院

08:50~09:00

Surgery versus concurrent chemoradiotherapy for resectable cⅢA-N2 NSCLC: A propensity score matched analysis

孙鑫中国医学科学院肿瘤医院

肺癌口头报告专场-论文交流-第二节

主持人：束永前、谷力加

09:00~09:10

Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment (Chinese subgroup Analysis)

张力广州中山大学肿瘤防治中心

09:10~09:20

Afatinib in patients (pts) with advanced HER2 mutation-positive (m+) NSCLC previously treated with chemotherapy (CT)

周彩存上海同济大学附属肺科医院

09:20~09:30

Long-term response to first-line afatinib in patients with advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of LUX-Lung (LL) 3, 6 and 7

吴一龙广东省人民医院

09:30~09:40

Analysis of EGFR mutation status in CSF and blood in lung adenocarcinoma patients with EGFR mutation and CNS metastasis

Sen Yang 河南省肿瘤医院

09:40~09:50

局限期小细胞肺癌胸部放疗的时间安排比剂量提高更重要：对两项前瞻性研究的平行回顾比较

胡晓浙江省肿瘤医院

09:50~10:00

中国晚期非小细胞肺癌(NSCLC)患者EGFR TKI耐药后T790M突变率

程颖吉林省肿瘤医院

10:00~10:10

洛铂联合紫杉醇与卡铂联合紫杉醇一线治疗局部晚期或转移性非小细胞肺癌有效性和安全性的随机、对照、多中心Ⅲ期临床研究

秦叔逵解放军南京八一医院全军肿瘤中心